Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of <sup>90</sup>Y-Ibritumomab Tiuxetan Response-Reference-Cited by-同舟云学术

Positron Emission Tomography/Computed Tomography before Treatment as a Predictor of ⁹⁰Y-Ibritumomab Tiuxetan Response

Published:2018-08-01 Issue:3 Volume:68 Page:151-156
ISSN:1343-2826
Container-title:The Kitakanto Medical Journal
language:en
Short-container-title:kmj

Author:

Yudistiro Ryan¹²,Heryanto Yusri Dwi¹,Kodaira Sayaka¹,Higuchi Tetsuya¹,Arisaka Yukiko¹,Tokue Azusa¹,Taketomi-Takahashi Ayako¹,Tsukamoto Norifumi³,Yokohama Akihiko⁴,Handa Hiroshi⁵,Koiso Hiromi⁶,Ishizaki Takuma⁵,Tsushima Yoshito¹

Affiliation:

1. Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine

2. Department of Nuclear Medicine, MRCCC Siloam Hospital, School of Medicine of Universitas Pelita Harapan

3. Oncology Center, Gunma University Hospital

4. Blood Transfusion Services, Gunma University Hospital

5. Department of Hematology, Gunma University Hospital

6. Infection Control and Prevention Center, Gunma University Hospital

Publisher

Kitakanto Medical Society

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/kmj/68/3/68_151/_pdf

Reference28 articles.

1. 1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.

2. 2. Prevodnik VK, Lavren J, Horvat M, et al. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol 2011; 6: 1-6.

3. 3. Fisher RI. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment. Semin Oncol 2003; 30: 3-9..

4. 4. Bodet-Milin C, Eugène T, Gastinne T, et al. The role of FDG-PET scanning in assessing lymphoma in 2012. Diagn Interv Imaging 2013; 94: 158-168.

5. 5. Witzig TE. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.